Air Doctor Raises $20 Million To Grow its Global Footprint
Medical care and travel startup Air Doctor has secured $20M in funding for scaling the company globally. This second round of investment capitalizes on the worldwide influx in travelers after the Covid-19 pandemic and will enable the company to enter its next phase of growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531005013/en/
The Air Doctor Team (Photo: Business Wire)
Air Doctor, raised $20 million, led by Lightspeed Venture Partners. Joining this round are Vintage Investment Partners and Munich Re Ventures, alongside The Phoenix, one of Israel's leading insurance providers, as well as Kamet Ventures, which led the company’s previous round.
Founded by Jenny Cohen Derfler, Efrat Sagi Ofir, Yam Derfler and Yegor Kurbachev, Air Doctor has previously raised $10.9 million since its launch in 2018. The startup currently employs over 60 people based in Israel and Europe.
The Air Doctor platform connects travelers who fall ill abroad with local private doctors through an easy-to-use mobile and web app. Air Doctor’s outpatient medical network covers 74 countries and includes over 20,000 medical professionals who provide either in-person or telemedicine consultations. Following the Covid-19 pandemic, medical assistance while traveling has become a major concern for travelers and insurers alike. Air Doctor’s platform provides the assurance travelers need to enjoy their trip.
In addition to bringing on board more developers to work on product customization, Air Doctor will use the new investment to hire new employees and open additional offices internationally. The company also has plans to expand the product and marketing teams, and the vetted medical professional network, particularly in the US and Europe.
In 2020, the COVID-19 outbreak brought the world to a standstill, with unprecedented and unanticipated consequences affecting people's lives and global economies. The travel and tourism sector experienced a severe economic slowdown as a result of stringent quarantine regulations and travel restrictions.
“As the world emerges from COVID-19, people have resumed travel, with a greater demand for suitable travel insurance and digital solutions. The pandemic has forced the industry to reassess local medical treatment available for travelers. Today, travelers testing positive for the Coronavirus will be able to seek medical care in the local communities they are in rather than in hospitals.” said Jenny Cohen Derfler, CEO and Founder of Air Doctor. “Air Doctor has become one of the fastest-growing startups, with tens of thousands registered users and many more accessing the network worldwide. Today the company offers a unique and distinctive digital product with almost no competition worldwide.” Said CEO Cohen Derfler
According to the World Economic Forum’s recent survey, the travel industry is expected to fully recover by 2024. Additionally, many countries may mandate travel insurance coverage. These two factors will create a dramatic surge in the need for better travel insurance. Furthermore, insurers facing travelers’ demands are seeking to expand their offer of digital, physical and online healthcare coverage to provide an improved customer experience and reduce claim costs.
“Building our partner and investor network will be an ongoing endeavor, as well as boosting our R&D capabilities and end-user activation. We’re also on the lookout to find new team members who are keen to join an exciting startup that is expanding globally,” said Efrat Sagi-Ofir, Co-Founder and Chief Revenue Officer of Air Doctor.
“Air Doctor addresses a major pain point for the health and travel insurance industry, and Lightspeed is excited to lead the company’s new $20 million funding round. Air Doctor continues to prove itself as an innovator in travel health by digitizing a significant aspect of the travel experience,” said Yoni Cheifetz, Partner at Lightspeed. “
About Air Doctor
Launched in Israel in 2018, Air Doctor is a startup that connects travelers seeking medical attention with local doctors whilst abroad through their intuitive mobile and desktop app. With a global network of over 20,000 medical professionals across 2,000 cities in 74 countries, Air Doctor provides travelers with peace of mind and aims to make healthcare accessible to everyone, everywhere.
About Lightspeed
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, Affirm, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. www.lsvp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005013/en/
Contact information
Yuval Zimerman, yuval.z@air-dr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 13:30:00 EET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 13:00:00 EET | Press release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 11:00:00 EET | Press release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo Secures OCC Approval to Convert to Federally Chartered National Trust Bank13.12.2025 03:10:00 EET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, today announced that the Office of the Comptroller of the Currency (“OCC”) approved its application to convert BitGo Trust Company, Inc., a South Dakota-chartered trust company, to a national bank named BitGo Bank & Trust, National Association (N.A.). With today’s OCC approval of its conversion, BitGo’s Trust Company subsidiary is now operating as BitGo Bank & Trust, National Association (N.A.). BitGo Bank & Trust, N.A. will operate under a single, uniform federal supervisory regime, enabling it to deliver the clarity, governance, and regulatory certainty institutions expect from a federally regulated fiduciary. This approval reinforces BitGo’s position as an institutional foundation for the modern financial system, combining bank-level oversight with the security, compliance, and scalability that define BitGo’s infrastructure. Under the national bank charter, and subject to applicable law and OCC requirements, B
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 18:10:00 EET | Press release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom